tetano
Editor, Senior Moderator
Eur Respir J
. 2020 Dec 10;2003481.
doi: 10.1183/13993003.03481-2020. Online ahead of print.
Cardiopulmonary recovery after COVID-19 - an observational prospective multi-center trial
Thomas Sonnweber[SUP] 1 2 [/SUP], Sabina Sahanic[SUP] 1 2 [/SUP], Alex Pizzini[SUP] 1 [/SUP], Anna Luger[SUP] 3 [/SUP], Christoph Schwabl[SUP] 3 [/SUP], Bettina Sonnweber[SUP] 4 [/SUP], Katharina Kurz[SUP] 1 [/SUP], Sabine Koppelst?tter[SUP] 1 [/SUP], David Haschka[SUP] 1 [/SUP], Verena Petzer[SUP] 5 [/SUP], Anna Boehm[SUP] 1 [/SUP], Magdalena Aichner[SUP] 1 [/SUP], Piotr Tymoszuk[SUP] 1 [/SUP], Daniela Lener[SUP] 6 [/SUP], Markus Theurl[SUP] 6 [/SUP], Almut Lorsbach-K?hler[SUP] 1 [/SUP], Amra Tancevski[SUP] 1 [/SUP], Anna Schapfl[SUP] 4 [/SUP], Marc Schaber[SUP] 4 [/SUP], Richard Hilbe[SUP] 1 [/SUP], Manfred Nairz[SUP] 1 [/SUP], Bernhard Puchner[SUP] 7 [/SUP], Doris H?ttenberger[SUP] 1 [/SUP], Christoph Tschurtschenthaler[SUP] 1 [/SUP], Malte A?hoff[SUP] 1 [/SUP], Andreas Peer[SUP] 8 [/SUP], Frank Hartig[SUP] 8 [/SUP], Romuald Bellmann[SUP] 8 [/SUP], Michael Joannidis[SUP] 8 [/SUP], Can Gollmann-Tepek?yl?[SUP] 9 [/SUP], Johannes Holfeld[SUP] 9 [/SUP], Gudrun Feuchtner[SUP] 3 [/SUP], Alexander Egger[SUP] 10 [/SUP], Gregor Hoermann[SUP] 10 11 12 [/SUP], Andrea Schroll[SUP] 1 [/SUP], Gernot Fritsche[SUP] 1 [/SUP], Sophie Wildner[SUP] 1 [/SUP], Rosa Bellmann-Weiler[SUP] 1 [/SUP], Rudolf Kirchmair[SUP] 6 7 [/SUP], Raimund Helbok[SUP] 13 [/SUP], Helmut Prosch[SUP] 14 [/SUP], Dietmar Rieder[SUP] 15 [/SUP], Zlatko Trajanoski[SUP] 15 [/SUP], Florian Kronenberg[SUP] 16 [/SUP], Ewald W?ll[SUP] 4 [/SUP], G?nter Weiss[SUP] 1 [/SUP], Gerlig Widmann[SUP] 3 [/SUP], Judith L?ffler-Ragg[SUP] 1 [/SUP], Ivan Tancevski[SUP] 1 [/SUP]
Affiliations
Abstract
Background: After the 2002/2003 SARS outbreak, 30% of survivors exhibited persisting structural pulmonary abnormalities. The long-term pulmonary sequelae of coronavirus disease 2019 (COVID-19) are yet unknown, and comprehensive clinical follow-up data are lacking.
Methods: In this prospective, multicentre, observational study, we systematically evaluated the cardiopulmonary damage in subjects recovering from COVID-19 at 60 and 100 days after confirmed diagnosis. We conducted a detailed questionnaire, clinical examination, laboratory testing, lung function analysis, echocardiography, and thoracic low-dose computed tomography (CT).
Results: Data from 145 COVID-19 patients were evaluated, and 41% of all subjects exhibited persistent symptoms 100 days after COVID-19 onset, with dyspnea being most frequent (36%). Accordingly, patients still displayed an impaired lung function, with a reduced diffusing capacity in 21% of the cohort being the most prominent finding. Cardiac impairment, including a reduced left ventricular function or signs of pulmonary hypertension, was only present in a minority of subjects. CT scans unveiled persisting lung pathologies in 63% of patients, mainly consisting of bilateral ground-glass opacities and/or reticulation in the lower lung lobes, without radiological signs of pulmonary fibrosis. Sequential follow-up evaluations at 60 and 100 days after COVID-19 onset demonstrated a vast improvement of both, symptoms and CT abnormalities over time.
Conclusion: A relevant percentage of post-COVID-19 patients presented with persisting symptoms and lung function impairment along with pulmonary abnormalities more than 100 days after the diagnosis of COVID-19. However, our results indicate a significant improvement in symptoms and cardiopulmonary status over time.
. 2020 Dec 10;2003481.
doi: 10.1183/13993003.03481-2020. Online ahead of print.
Cardiopulmonary recovery after COVID-19 - an observational prospective multi-center trial
Thomas Sonnweber[SUP] 1 2 [/SUP], Sabina Sahanic[SUP] 1 2 [/SUP], Alex Pizzini[SUP] 1 [/SUP], Anna Luger[SUP] 3 [/SUP], Christoph Schwabl[SUP] 3 [/SUP], Bettina Sonnweber[SUP] 4 [/SUP], Katharina Kurz[SUP] 1 [/SUP], Sabine Koppelst?tter[SUP] 1 [/SUP], David Haschka[SUP] 1 [/SUP], Verena Petzer[SUP] 5 [/SUP], Anna Boehm[SUP] 1 [/SUP], Magdalena Aichner[SUP] 1 [/SUP], Piotr Tymoszuk[SUP] 1 [/SUP], Daniela Lener[SUP] 6 [/SUP], Markus Theurl[SUP] 6 [/SUP], Almut Lorsbach-K?hler[SUP] 1 [/SUP], Amra Tancevski[SUP] 1 [/SUP], Anna Schapfl[SUP] 4 [/SUP], Marc Schaber[SUP] 4 [/SUP], Richard Hilbe[SUP] 1 [/SUP], Manfred Nairz[SUP] 1 [/SUP], Bernhard Puchner[SUP] 7 [/SUP], Doris H?ttenberger[SUP] 1 [/SUP], Christoph Tschurtschenthaler[SUP] 1 [/SUP], Malte A?hoff[SUP] 1 [/SUP], Andreas Peer[SUP] 8 [/SUP], Frank Hartig[SUP] 8 [/SUP], Romuald Bellmann[SUP] 8 [/SUP], Michael Joannidis[SUP] 8 [/SUP], Can Gollmann-Tepek?yl?[SUP] 9 [/SUP], Johannes Holfeld[SUP] 9 [/SUP], Gudrun Feuchtner[SUP] 3 [/SUP], Alexander Egger[SUP] 10 [/SUP], Gregor Hoermann[SUP] 10 11 12 [/SUP], Andrea Schroll[SUP] 1 [/SUP], Gernot Fritsche[SUP] 1 [/SUP], Sophie Wildner[SUP] 1 [/SUP], Rosa Bellmann-Weiler[SUP] 1 [/SUP], Rudolf Kirchmair[SUP] 6 7 [/SUP], Raimund Helbok[SUP] 13 [/SUP], Helmut Prosch[SUP] 14 [/SUP], Dietmar Rieder[SUP] 15 [/SUP], Zlatko Trajanoski[SUP] 15 [/SUP], Florian Kronenberg[SUP] 16 [/SUP], Ewald W?ll[SUP] 4 [/SUP], G?nter Weiss[SUP] 1 [/SUP], Gerlig Widmann[SUP] 3 [/SUP], Judith L?ffler-Ragg[SUP] 1 [/SUP], Ivan Tancevski[SUP] 1 [/SUP]
Affiliations
- PMID: 33303539
- DOI: 10.1183/13993003.03481-2020
Abstract
Background: After the 2002/2003 SARS outbreak, 30% of survivors exhibited persisting structural pulmonary abnormalities. The long-term pulmonary sequelae of coronavirus disease 2019 (COVID-19) are yet unknown, and comprehensive clinical follow-up data are lacking.
Methods: In this prospective, multicentre, observational study, we systematically evaluated the cardiopulmonary damage in subjects recovering from COVID-19 at 60 and 100 days after confirmed diagnosis. We conducted a detailed questionnaire, clinical examination, laboratory testing, lung function analysis, echocardiography, and thoracic low-dose computed tomography (CT).
Results: Data from 145 COVID-19 patients were evaluated, and 41% of all subjects exhibited persistent symptoms 100 days after COVID-19 onset, with dyspnea being most frequent (36%). Accordingly, patients still displayed an impaired lung function, with a reduced diffusing capacity in 21% of the cohort being the most prominent finding. Cardiac impairment, including a reduced left ventricular function or signs of pulmonary hypertension, was only present in a minority of subjects. CT scans unveiled persisting lung pathologies in 63% of patients, mainly consisting of bilateral ground-glass opacities and/or reticulation in the lower lung lobes, without radiological signs of pulmonary fibrosis. Sequential follow-up evaluations at 60 and 100 days after COVID-19 onset demonstrated a vast improvement of both, symptoms and CT abnormalities over time.
Conclusion: A relevant percentage of post-COVID-19 patients presented with persisting symptoms and lung function impairment along with pulmonary abnormalities more than 100 days after the diagnosis of COVID-19. However, our results indicate a significant improvement in symptoms and cardiopulmonary status over time.